Literature DB >> 22183840

Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial.

Jared M Baeten1, Stewart E Reid, Sinead Delany-Moretlwe, James P Hughes, Richard S Wang, Ellen Wilcox, Mohammed Limbada, Godspower Akpomiemie, Lawrence Corey, Anna Wald, Connie Celum.   

Abstract

In a randomized trial among African women with recurrent genital herpes, episodic acyclovir therapy resulted in modestly greater likelihood of lesion healing (hazard ratio [HR] = 1.48, P = 0.098; mean, 5.1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405).

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22183840      PMCID： PMC3244838          DOI： 10.1097/OLQ.0b013e31823b50c6

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN： 0148-5717            Impact factor:   2.830


  15 in total

1.  Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries.

Authors:  Catherine Corbell; Andy Stergachis; Francis Ndowa; Patrick Ndase; Linda Barnes; Connie Celum
Journal:  Sex Transm Dis       Date:  2010-08       Impact factor: 2.830

2.  Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR.

Authors:  Keith R Jerome; Meei-Li Huang; Anna Wald; Stacy Selke; Lawrence Corey
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

3.  Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi.

Authors:  Sam Phiri; Irving F Hoffman; Helen A Weiss; Francis Martinson; Naomi Nyirenda; Debbie Kamwendo; Susan A Fiscus; Cheng-Yen Chen; William C Miller; Len van der Hoeven; David Chilongozi; Myron S Cohen; Philippe Mayaud
Journal:  Sex Transm Infect       Date:  2010-05-05       Impact factor: 3.519

4.  Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.

Authors:  Jonathan Fuchs; Connie Celum; Jing Wang; James Hughes; Jorge Sanchez; Frances Cowan; Stewart Reid; Sinead Delany-Moretlwe; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

5.  Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes.

Authors:  A E Nilsen; T Aasen; A M Halsos; B R Kinge; E A Tjøtta; K Wikström; A P Fiddian
Journal:  Lancet       Date:  1982-09-11       Impact factor: 79.321

6.  Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial.

Authors:  Gabriela Paz-Bailey; Maya Sternberg; Adrian J Puren; Lauri E Markowitz; Ronald Ballard; Sinead Delany; Sarah Hawkes; Okey Nwanyanwu; Caroline Ryan; David A Lewis
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

7.  Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.

Authors:  Philippe Mayaud; Jérôme Legoff; Helen A Weiss; Gérard Grésenguet; Khonde Nzambi; Hicham Bouhlal; Eric Frost; Jacques Pépin; Jean-Elie Malkin; Richard J Hayes; David C W Mabey; Laurent Bélec
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

8.  Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.

Authors:  Connie Celum; Anna Wald; James Hughes; Jorge Sanchez; Stewart Reid; Sinead Delany-Moretlwe; Frances Cowan; Martin Casapia; Abner Ortiz; Jonathan Fuchs; Susan Buchbinder; Beryl Koblin; Sheryl Zwerski; Scott Rose; Jing Wang; Lawrence Corey
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

9.  Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.

Authors:  Rachna Gupta; Anna Wald; Elizabeth Krantz; Stacy Selke; Terri Warren; Mauricio Vargas-Cortes; Gerri Miller; Lawrence Corey
Journal:  J Infect Dis       Date:  2004-09-20       Impact factor: 5.226

10.  Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition.

Authors:  Jia Zhu; Florian Hladik; Amanda Woodward; Alexis Klock; Tao Peng; Christine Johnston; Michael Remington; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440
View more
  2 in total

Review 1.  Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.

Authors:  Ruanne V Barnabas; Connie Celum
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

2.  High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection.

Authors:  Kamini Gounder; Nagavelli Padayachi; Jaclyn K Mann; Mopo Radebe; Mammekwa Mokgoro; Mary van der Stok; Lungile Mkhize; Zenele Mncube; Manjeetha Jaggernath; Tarylee Reddy; Bruce D Walker; Thumbi Ndung'u
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.